Astrazeneca Pharma India Ltd
NSE:ASTRAZEN
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
6 698.65
10 509.5
|
| Price Target |
|
We'll email you a reminder when the closing price reaches INR.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Operating Margin
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Peer Comparison
| Country | Company | Market Cap |
Operating Margin |
||
|---|---|---|---|---|---|
| IN |
|
Astrazeneca Pharma India Ltd
NSE:ASTRAZEN
|
208.1B INR |
Loading...
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
1T USD |
Loading...
|
|
| UK |
|
Dechra Pharmaceuticals PLC
LSE:DPH
|
440.4B GBP |
Loading...
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
524.6B USD |
Loading...
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
274.9B CHF |
Loading...
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
219.9B CHF |
Loading...
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
209.8B GBP |
Loading...
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
276.4B USD |
Loading...
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.7T DKK |
Loading...
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
218B USD |
Loading...
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
147.2B USD |
Loading...
|
Market Distribution
| Min | -153 833.3% |
| 30th Percentile | 2.7% |
| Median | 7.3% |
| 70th Percentile | 13.2% |
| Max | 9 977% |
Other Profitability Ratios
Astrazeneca Pharma India Ltd
Glance View
AstraZeneca Pharma India Ltd., a pivotal name in the Indian pharmaceutical landscape, is an integral arm of the global biopharmaceutical titan, AstraZeneca PLC headquartered in Cambridge, UK. The company has woven itself into the fabric of healthcare by consistently delivering novel medicines designed to combat a range of illnesses that include oncology, cardiovascular, renal, and metabolic diseases, as well as respiratory ailments. In India, AstraZeneca Pharma has carved out a reputation for not only introducing cutting-edge research and development capabilities but also adapting its global innovations to fit the unique demands of the local market. By leveraging a robust pipeline of therapeutic solutions, the company plays a crucial role in the intersection of healthcare and technology, aiming to improve patient outcomes through personalized medicine and bioscience-led innovations. The business model of AstraZeneca Pharma India is anchored in its commitment to research-driven innovation and strategic partnerships. Revenue streams are tightly interlinked with the company’s ability to successfully commercialize its extensive portfolio of patented medicines. AstraZeneca focuses on maintaining strong relationships with healthcare professionals and stakeholders, which are pivotal in driving prescriptions and ensuring the adoption of its novel therapies. Sales and distribution channels are fortified through collaborations with hospitals, pharmacies, and other healthcare providers, ensuring a broad reach across the country. The company continues to invest in its capabilities to educate and train medical professionals, thus enhancing its influence in the medical community and reinforcing its position as a market leader in providing life-saving medications.
See Also
Operating Margin is calculated by dividing the Operating Income by the Revenue.
The current Operating Margin for Astrazeneca Pharma India Ltd is 13.6%, which is above its 3-year median of 13.5%.
Over the last 3 years, Astrazeneca Pharma India Ltd’s Operating Margin has increased from 11.7% to 13.6%. During this period, it reached a low of 9.1% on Sep 30, 2024 and a high of 17.7% on Jun 30, 2023.